Navigation Links
New Trial Studies Link Between Stroke and Atrial Fibrillation
Date:12/7/2010

CHICAGO, Dec. 7, 2010 /PRNewswire-USNewswire/ -- One evening last March, Larry Ambrose left his bed in the middle of the night to check the time. Much to the 71-year-old's surprise, he was only able to see three out of the four glowing numbers on the digital clock in his kitchen. Ambrose returned to bed, but within days was hospitalized for what was later diagnosed as a stroke. After extensive testing, his physicians told him they could not determine the cause.  

Cryptogenic stroke, or stroke of undetermined cause, accounts for 25 percent of all strokes. In many of these cases, physicians believe atrial fibrillation may occur without the patient's knowledge, causing the stroke. To better understand the connection between atrial fibrillation and stroke, Northwestern Medicine physician researchers from cardiology and neurology have teamed up to monitor people diagnosed with a cryptogenic strokes for intermittent atrial fibrillation as part of a study called CRYSTAL AF (Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation after Cryptogenic Stroke).  

During atrial fibrillation, the most common type of arrhythmia (abnormal heart beat), the heart's upper chambers, or atria, quiver rather than beat; this allows blood to stay in the chamber and potentially cause a clot. If the clot travels from the heart and reaches the brain, a stroke is imminent. "Patients with atrial fibrillation are at a greater risk for stroke than the general population," said Rod Passman, MD, medical director for the Center for Atrial Fibrillation at the Bluhm Cardiovascular Institute of Northwestern Memorial Hospital and associate professor of cardiology at Northwestern University's Feinberg School of Medicine. "Fifteen percent of all strokes are in patients with atrial fibrillation."  

The CRYSTAL AF trial will enroll approximately 450 people who have been diagnosed with a cryptogenic stroke across 55 centers. Approximately half will be
'/>"/>

SOURCE Northwestern Memorial Hospital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
2. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
3. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
4. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
5. FDA Clears GeNO LLCs Investigational New Drug Application for Clinical Trials With Its NITROSYL™ Inhaled Nitric Oxide System
6. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
7. ArterX™ Clinical Trial Results Announced at Veith Meeting
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Quietly, sedately, Morocco,s pharmaceutical sector is ... industry is strong, with a well-developed base of local ... One place where the quality of Moroccan ... has quietly become the second largest African exporter of ... Indeed, Moroccan pharma companies have been making inroads as ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... that a new market research report is available in ... Sales Forces , http://www.reportlinker.com/p0154035/Reportlinker-Adds-Reinventing-Pharmaceutical-Sales-Forces.html ... groups and leaner economic times have forced a new ... the previous decade is dead. Faced with the challenge ...
... Oct. 8 Ethicon Endo-Surgery today announced the company ... for the research and design process used in the ... company was recognized among thousands of entries for its ... collaboration with surgeons across the globe to identify specific ...
Cached Medicine Technology:Reportlinker Adds Reinventing Pharmaceutical Sales Forces 2Reportlinker Adds Reinventing Pharmaceutical Sales Forces 3Reportlinker Adds Reinventing Pharmaceutical Sales Forces 4Reportlinker Adds Reinventing Pharmaceutical Sales Forces 5Reportlinker Adds Reinventing Pharmaceutical Sales Forces 6Reportlinker Adds Reinventing Pharmaceutical Sales Forces 7Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM) 2Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM) 3
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... Hartford, CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil ... 2,175 mile trek of the Appalachian Trail by stepping off Springer Mountain and ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
Breaking Medicine News(10 mins):Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... of the disease , , THURSDAY, Jan. 31 (HealthDay News) ... with severe and non-severe asthma, something that could help ... to treatment. , The study, from the Severe Asthma ... asthma and 382 people with mild or moderate asthma. ...
... Corporation (NYSE: HMN ) will release its fourth ... market closes. The,earnings press release will be available shortly ... at http://www.horacemann.com .,Management will host a conference call ... at 10:00 a.m. ET., The call will be ...
... Jan. 31 MedWaves, Inc. announces the receipt,of ... System for general surgery use for the coagulation ... of a microwave generator,and single patient use sterile ... of a product portfolio and indications for use ...
... Jan. 31 Wild Child, an Australian-based,natural health care ... family products containing only natural or nature identical ingredients,announced ... be available in,44 states across the United States through ... and CEO Leanne Preston said the agreement was the,result ...
... University of Oregon scientists say they have identified a ... cells to form into muscles in zebrafish. , Much ... go to lunch, the trigger gene, which is identified ... for muscle formation to begin, a process known as ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
Cached Medicine News:Health News:Severe Asthma Unlike Mild Asthma 2Health News:Horace Mann Announces Fourth Quarter Earnings Release and Conference Call 2Health News:MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... for the quantitative determination of ... or plasma. Two vials, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Medicine Products: